<- Go Home

Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; provision of chemical macromolecule contract development manufacture organization (CDMO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solutions. In addition, the company is involved in development and drug product manufacturing; provision of pharmaceutical analysis and testing services; medical research and development; manufacturing, sale, and development of medicine raw materials and relevant products; sale of drug products; pharmaceuticals and chemical manufacturing; wholesaling and retailing of drugs; sale, import and export trade; information technology; technology development; and research and experimental development activities. The company was founded in 1998 and is headquartered in Tianjin, China.

Market Cap

CNY 26.9B

Volume

4.7M

Cash and Equivalents

CNY 5.8B

EBITDA

CNY 1.1B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

CNY 2.4B

Profit Margin

41.55%

52 Week High

CNY 94.28

52 Week Low

CNY 59.55

Dividend

1.42%

Price / Book Value

1.62

Price / Earnings

28.89

Price / Tangible Book Value

1.68

Enterprise Value

CNY 19.6B

Enterprise Value / EBITDA

17.60

Operating Income

CNY 618.7M

Return on Equity

5.44%

Return on Assets

1.98

Cash and Short Term Investments

CNY 7.6B

Debt

CNY 324.8M

Equity

CNY 16.9B

Revenue

CNY 5.8B

Unlevered FCF

-CNY 425.2M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches